Direct delivery of aerosolized vaccines to the respiratory mucosa elicits both systemic and mucosal responses. This vaccine strategy has not been tested for Ebola virus (EBOV) or other hemorrhagic fever viruses. Here, we examined the immunogenicity and protective efficacy of an aerosolized human parainfluenza virus type 3–vectored vaccine that expresses the glycoprotein (GP) of EBOV (HPIV3/EboGP) delivered to the respiratory tract.
Original Source [2]
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/feature-article/aerosolized-ebola-vaccine-protects-primates-and-elicits-lung-resident-t-cell
[2] http://www.jci.org/articles/view/81532/pdf
[3] http://admin.indiaenvironmentportal.org.in/category/author/michelle-meyer
[4] http://admin.indiaenvironmentportal.org.in/category/author/tania-garron
[5] http://admin.indiaenvironmentportal.org.in/category/author/ndongala-m-lubaki-et-al
[6] http://admin.indiaenvironmentportal.org.in/category/journal/journal-clinical-investigation
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/ebola-virus-disease-ebola-hemorrhagic-fever
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[9] http://admin.indiaenvironmentportal.org.in/category/thesaurus/monkey
[10] http://admin.indiaenvironmentportal.org.in/category/thesaurus/vaccination
[11] http://admin.indiaenvironmentportal.org.in/category/thesaurus/research
